KRYS Stock Krystal Biotech, Inc.
STRONG BUY US · NasdaqGSCommercial momentum, bullish analyst revision, and multiple 2026 pipeline readouts support further upside.
Future value: $395.44 (+26.07%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Jefferies raised target after stronger U.S. demand and pipeline progress.
- ▾Below 50-day MA (-7.33%)
- ▸Above 200-day MA — long-term uptrend
- ▸~26% upside to price target
Is KRYS a buy right now?
Trend: KRYS is trading below the 50-day average (-7.33%), RSI 47 — neutral momentum, with a 3-month return of -13.88%.
Valuation & quality: Krystal Biotech, Inc. trades on a trailing P/E of 39.3, forward P/E 35.0, price-to-book 6.83; fundamentals show net margin 54.8%, return on equity 20.1%, revenue growth 24.1% year on year.
Analyst consensus: 9 analysts have a mean 12-month price target of $395.44 (+26.1% vs the last close; range $284.00 – $474.00), consensus rating “strong buy”.
Our screen: STRONG BUY (score 4) — Commercial momentum, bullish analyst revision, and multiple 2026 pipeline readouts support further upside.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -6.30% | +1.50% | +17.80% | +20.30% | -8.20% | +5.30% | -7.50% | -5.70% |
Fundamentals
Analyst price target
Technical signals
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
Sector: Healthcare · Industry: Biotechnology · United States · 295 employees · Website
Related Biotech picks
Browse: all US stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.